Unifarin2 mg

Unifarin 2 mg is indicated in the following conditions- Prophylaxis and/or treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement Indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction Prophylaxis and treatment of venous thrombosis and pulmonary embolism Transient ischaemic attacks.

Anti-coagulants, Oral Anti-coagulants

Unifarin 2 mg inhibits synthesis of vit K-dependent coagulation factors II, VII, IX, and X as well as the anticoagulant protein C and its cofactor protein S. These clotting factors are biologically activated by the addition of carboxyl groups to key glutamic acid residues w/in the proteins' structure. Unifarin 2 mg competitively inhibits the C1 subunit of the multi-unit vit K epoxide reductase (VKORC1) enzyme complex, thus depleting functional vit K reserves and hence reduces synthesis of active clotting factors.

Whenever possible, the baseline prothrombin time should be determined but the initial dose should not be delayed whilst awaiting the result.The usual adult induction dose of Unifarin 2 mg: 10 mg daily for 2 days. The subsequent maintenance dose depends upon the prothrombin time, reported as INR (international normalized ratio). The daily maintenance dose of Unifarin 2 mg is usually 3 to 9 mg (taken at the same time each day). The maintenance dose is omitted if the prothrombin time is excessively prolonged. Once the maintenance dose is established in the therapeutic range, it is rarely necessary to alter. In emergencies, anticoagulant therapy should be initiated with heparin and Unifarin 2 mg together. Where there is less urgency, as in patients disposed to or at special risk of thromboembolism, anticoagulant therapy may be initiated with Unifarin 2 mg alone. Control tests must be made at regular intervals and maintenance dosage further adjusted according to the results obtained.Use in children: Safety and efficacy in children <18 years old have not been established. However, there is evidence of use and the initial dose is usually 0.1 mg.kg-1.d-1 adjusted subsequently to aim for an INR range the same as in adults.

Oral anticoagulants have a greater potential for clinically significant drug interactions. Unifarin 2 mg all patients about potential hazards and instruct against taking any drug, including non-prescription products, without the advice of a physician.

Actual or potential haemorrhagic conditions, eg. Peptic ulcer, or to patients with uncontrolled hypertension Severe hepatic or renal disease Pregnancy Known hypersensitivity to Unifarin 2 mg Bacterial endocarditis Its use within 24 hours following surgery or labour should be undertaken with caution, if at all.

Hemorrhage is the principal adverse effect of oral anticoagulants. Other adverse reactions include nausea, vomiting, diarrhea, hypersensitivity, rash, alopecia, and unexplained drop in haematocrit, "purple toes", skin necrosis, jaundice, and hepatic dysfunction.

Unifarin 2 mg is contraindicated in the first trimester of pregnancy because of the risk of teratogenicity. It should not be used in women who are or may become pregnant because the drug passes through the placental barrier and may cause fatal hemorrhage to the fetus. Unifarin 2 mg appears in the milk of nursing mothers in an inactive form. Infants nursed by mothers treated with Unifarin 2 mg had no change in prothrombin times. Effects in premature infants have not been evaluated.

Periodic determination of prothrombin time (PT)/international normalized ratio (INR) or other suitable coagulation test is essential. Numerous factors, alone or in combination, including travel, changes in diet, environment, physical state and medication may influence response of the patient to anticoagulants. It is generally good practice to monitor the patient's response with additional PT/INR determination in the period immediately after discharge from the hospital, and whenever other medications are initiated, discontinued or taken irregularly. The following factors may exaggerate the effects of Unifarin 2 mg and necessitate a reduction in dosage; loss of weight, elderly subject, acute illness, deficient renal function, decreased dietary intake of vitamin K, administration of certain drugs (see drug interaction). Factors which may call for an increase in maintenance dosage include weight gain, diarrhea and vomiting, increased intake of vitamin K, fats and oils, and the administration of certain drugs (see drug interaction). Careful additional laboratory control is necessary if the patient is to be changed from one formulation to another. Reversal of Unifarin 2 mg anticoagulation by vitamin K takes several days. In emergency situations fresh frozen plasma should be given.

If hemorrhage occurs or a potential bleeding state arises, excessive depression of the coagulation activity can be corrected by temporary withdrawal of Unifarin 2 mg accompanied, if necessary, by infusion of fresh-frozen plasma or whole blood. Vitamin K, 5 to 10 mg orally or intravenously, may be required to supplement specific treatment with factor concentrates.

Replace cap securely and protect from light.